Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
Severe radiation dermatitis in patients with locally advanced head and neck cancer treated with concurrent radiation and cetuximab
American Journal of Clinical Oncology, 10/06/09
Koutcher LD et al. – Treatment with concurrent radiation and cetuximab for locally advanced HNC is a relatively new treatment modality, and the toxicities of this regimen are becoming better understood. We believe that the serious skin toxicities that these patients develop when treated with concomitant cetuximab occur more frequently than when patients are treated with concurrent cisplatin.
Methods- Retrospective review of HNC patients treated with concurrent cetuximab and radiation
- Patients treated in either definitive or loco-regionally recurrent setting with nonmetastatic disease who received their first dose of cetuximab from March 1, 2006 to January 1, 2008included
- 115 patients
- Serious radiation dermatitis noted in 26 (23%) patients (22 developed grade 3 dermatitis and 4 developed grade 4 dermatitis)
- 4 patients developed grade 4 dermatitis did so within radiation field
- Dermatitis manifested by spontaneous bleeding from involved skin, and in 1 case, skin necrosis
- Toxicities developed during fifth week of treatment
Today in Radiotherapy (XRT)...keeping you current
Receive free subspecialty "5-minute updates" via email
Radiation therapy and tamoxifen after breast-conserving surgery: Updated results of a 2×2 randomised clinical trial in patients with low risk of recurrence
European Journal of Cancer, 11/05/09
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
The Lancet Oncology - Online First, 11/11/09
Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck
Annals of Oncology, 11/10/09
Sponsor
Article Search
Sponsor


See Latest Articles


